Abstract: An example technique for treating a skin cancer condition includes administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer. An example composition includes a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition. An example composition includes a pharmaceutically effective amount of at least one anti-solar ultraviolet (anti-sUV) combination for preventing a skin cancer condition. The at least one anti-sUV combination is chosen from the combinations: avobenzone and octinoxate; octocrylene and zinc oxide; avobenzone, octocrylene, and titanium dioxide; or avobenzone, octocrylene, and zinc oxide.

Abstract: The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and/or skin cancer in a mammal.

Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1, R2, R3, R4 and ring A have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as anti-cancer agents.

Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1, R2, R3, R4 and ring A have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as anti-cancer agents.

Abstract: A method for detecting and/or measuring circulating TXA2 in a subject having or at risk of having colorectal cancer. Generally, the method includes obtaining a biological sample from the subject, measuring circulating TXA2 in the biological sample, and identifying the subject as having colorectal cancer if the circulating TXA2 in the biological sample is greater than a predetermined level. The method may be used as a diagnostic test and/or may be performed repeatedly to monitor the status of colorectal cancer in a subject over time.

Abstract: The invention provides compounds of the formula: and salts thereof that are useful as intermediates for preparing corresponding compounds of formula I: that are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer).

Abstract: A method for detecting and/or measuring circulating TXA2 in a subject having or at risk of having colorectal cancer. Generally, the method includes obtaining a biological sample from the subject, measuring circulating TXA2 in the biological sample, and identifying the subject as having colorectal cancer if the circulating TXA2 in the biological sample is greater than a predetermined level. The method may be used as a diagnostic test and/or may be performed repeatedly to monitor the status of colorectal cancer in a subject over time.

Abstract: Compounds are disclosed which are effective for inhibiting ?-catenin or disrupting a ?-catenin/Tcf-4 complex, and for causing effective attenuation of colon carcinogenesis. The compounds may be effective treatment for colorectal cancer (CRC) when administered in an effective dose to a patient afflicted therewith.

Abstract: The invention provides compounds of the formula: and salts thereof that are useful as intermediates for preparing corresponding compounds of formula I: that are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer).

Abstract: The invention provides a compound of formula I: or a salt thereof, wherein ring A and R1-R4 have any of the values defined in the specification. The compounds have activity as Aurora B kinase inhibitors and are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer).

Abstract: Compounds are disclosed which are effective for inhibiting ?-catenin or disrupting a ?-catenin/Tcf-4 complex, and for causing effective attenuation of colon carcinogenesis. The compounds may be effective treatment for colorectal cancer (CRC) when administered in an effective dose to a patient afflicted therewith.

Abstract: The invention provides a compound of formula I: or a salt thereof, wherein ring A and R1-R4 have any of the values defined in the specification. The compounds have activity as Aurora B kinase inhibitors and are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer).

Abstract: The invention provides methods, uses and compounds for treating cancers.

Abstract: Compositions and methods for treating, preventing, or ameliorating one or more symptoms, disorders, or conditions associated with particular c-Jun N-terminal kinase(s) (JNKs) activity are provided. Compositions contain small molecules such as pyrazoloanthrones.

Abstract: In one aspect, the present invention provides compounds having formula I or IV as shown below: as further defined herein. In additional aspects, the present invention provides compositions and kits comprising the compounds of the invention and methods for their use, for example, for the prevention or treatment of a cancer.

Abstract: In one aspect, the present invention provides compounds having formula I or IV as shown below: as further defined herein. In additional aspects, the present invention provides compositions and kits comprising the compounds of the invention and methods for their use, for example, for the prevention or treatment of a cancer.

Abstract: The present invention provides pharmaceutical compositions including: a combination of a compound of the formula (I) wherein R1 is C1-C6 alkyl and R2 is independently —H or —OH, or a pharmaceutically acceptable salt thereof; and a phorbol compound. The present invention also provides for these and other compositions and their use for the treatment of established cancers or tumors.

Abstract: The inhibition of AP-1 activity by dominant negative deletion mutants of c-jun is disclosed. This inhibition of AP-1 activity is shown to be associated with inhibition of tumor promoter-induced neoplastic transformation. Therefore, the invention relates to the utilization of dominant negative deletion mutants of c-jun which are inhibitory to tumor promotor-induced neoplastic transformation as therapeutic agents in the prevention and treatment of cancer in mammals.